Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient

Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient

314390

Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient

The first participant has been dosed in a Phase 1/2 clinical trial that is testing Intellia Therapeutics’ gene-editing therapy, NTLA-2002, in people with hereditary angioedema (HAE). “With the progress of our first-in-human clinical study evaluating NTLA-2002 for people living with HAE, we look forward to beginning clinical testing as we aim to develop a single-dose treatment for these patients,” John Leonard, MD, Intellia’s president and CEO, said in a press release. The Phase 1/2 trial (NCT05120830),…

You must be logged in to read/download the full post.